Cerevance announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer's disease utilizing Cerevance's proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. Under the terms of the agreement, Cerevance will receive a $25 million upfront payment and is eligible to receive development and commercial milestone payments totaling approximately $1.1 billion, in addition to potential royalties on sales of approved products derived from the collaboration.